Valeant Sells Dendreon, Other Assets for $2B
The sales of Dendreon and three skincare brands will help the troubled drug maker to reduce its $30 billion debt burden.
Regulator Bars Valeant Officers From Trading
A Canadian regulator issues a cease trade order after the troubled drug maker announces it would be late filing financial reports.
Ex-Valeant CFO Denies ‘Improper Conduct’
Howard Schiller says he is not to blame for the incorrect recognition of $58 million in revenue that has caused Valeant to restate its financial results.
Valeant Discloses SEC Probe
The pharmaceuticals company also canceled its 2016 financial guidance and delayed filing its fourth-quarter earnings report.